Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's Laboratories filed a 6-K providing a link to the audio recording of its Q4 FY2026 earnings call held on May | May 12, 2026 |
| BHST | 6-K | neutral | 4/10 | BioHarvest Sciences announced a $1.2 million Stage 2 CDMO contract for developing a rare fragrance compound using its Bo | May 12, 2026 |
| GNMSF | 6-K | neutral | 1/10 | Genmab announced a nominal capital increase of 2,346 shares (0.004% of share capital) from employee warrant exercises, r | May 12, 2026 |
| SKYE | PRESS-RELEASE | bearish | 7/10 | Skye Bioscience reported Q1 2026 EPS of -$0.32, missing consensus of -$0.29 by 10.3%, with a net loss of $12.5M vs $11.1 | May 12, 2026 |
| ZEOX | 8-K | neutral | 4/10 | Zeo ScientifiX announced that for the first time in company history, its unaudited monthly sales surpassed $1 million in | May 12, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's filed a routine 6-K reporting board meeting outcomes: re-appointment of an independent director, appointment | May 12, 2026 |
| KURA | PRESS-RELEASE | bullish | 7/10 | Kura Oncology announced that updated Phase 1 KOMET-007 data for ziftomenib in frontline AML will be presented at EHA 202 | May 12, 2026 |
| CLLS | 6-K | neutral | 3/10 | Cellectis announced upcoming presentations of Phase 1 data for lasme-cel (BALLI-01) and eti-cel (NATHALI-01) at the EHA | May 12, 2026 |
| EVAX | PRESS-RELEASE | neutral | 4/10 | Evaxion announced a poster presentation at the EHA 2026 Congress detailing preclinical data for EVX-04, an off-the-shelf | May 12, 2026 |
| BEAM | PRESS-RELEASE | bullish | 7/10 | Beam Therapeutics announced it will present updated biomarker data from the BEACON Phase 1/2 trial of ristoglogene autog | May 12, 2026 |
| MBRX | 8-K | neutral | 3/10 | Moleculin Biotech announced publication of an abstract at the EHA 2026 Congress showing no clinically significant cardio | May 12, 2026 |
| EVAX | 6-K | neutral | 3/10 | Evaxion announced it will present preclinical data for EVX-04, an off-the-shelf therapeutic AML vaccine, at the EHA 2026 | May 12, 2026 |
| CMND | 6-K | neutral | 3/10 | Clearmind Medicine announced it has dosed two additional participants in the fourth cohort of its Phase I/IIa trial for | May 12, 2026 |
| AAPG | 6-K | neutral | 2/10 | Ascentage Pharma announced management participation in three upcoming investor conferences (B. Riley, Stifel, Jefferies) | May 12, 2026 |
| BIAFW | 8-K | neutral | 4/10 | bioAffinity Technologies announced via an 8-K that unit sales of its CyPath Lung diagnostic test reached a record monthl | May 12, 2026 |
| CPRX | DEFA14A | neutral | 3/10 | Catalyst Pharmaceuticals filed additional definitive proxy soliciting materials (DEFA14A) containing an employee update | May 12, 2026 |
| CNTB | 8-K | neutral | 4/10 | Connect Biopharma reported Q1 2026 results with a net loss of $19.4M ($0.34/share), widening from a $10.3M loss ($0.19/s | May 12, 2026 |
| CNTB | PRESS-RELEASE | bearish | 6/10 | Connect Biopharma reported Q1 2026 net loss of $0.34 per share, significantly wider than the consensus estimate of -$0.2 | May 12, 2026 |
| COYA | 8-K | neutral | 4/10 | Coya Therapeutics entered into an at-the-market (ATM) equity sales agreement with Leerink Partners LLC, allowing the com | May 12, 2026 |
| AKTX | PRESS-RELEASE | neutral | 4/10 | Akari Therapeutics announced the grant of a major European patent (No. 3684773B1) providing broad composition-of-matter | May 12, 2026 |
| MANE | 8-K | neutral | 5/10 | Veradermics reported Q1 2026 results showing a net loss of $27.2M, widening from a $12.4M loss in Q1 2025, driven by inc | May 12, 2026 |
| CRBP | 8-K | mixed | 5/10 | Corbus Pharmaceuticals reported Q1 2026 net loss of $23.0M ($1.23/share), slightly beating the $1.26 consensus estimate. | May 12, 2026 |
| ACIU | 6-K | neutral | 2/10 | AC Immune announced the retirement of long-serving CEO Andrea Pfeifer at the June 11 AGM, with Board Chair Martin Zügel | May 12, 2026 |
| KLRS | 8-K | neutral | 4/10 | Kalaris Therapeutics reported Q1 2026 financial results, with net loss widening to $10.9M from $10.2M YoY and cash decre | May 12, 2026 |
| HMDCF | 6-K | neutral | 1/10 | HUTCHMED reported that all resolutions at its May 12, 2026 Annual General Meeting were passed, including re-election of | May 12, 2026 |
| IMNN | 8-K | bullish | 6/10 | Imunon reported Q1 2026 GAAP EPS of -$0.84, beating consensus of -$0.99 by 15%, but operating cash burn widened to -$4.0 | May 12, 2026 |
| PMVP | PRESS-RELEASE | bullish | 5/10 | PMV Pharma reported Q1 2026 EPS of -$0.34, beating consensus -$0.39 by 12.8%. The company also announced FDA Orphan Drug | May 12, 2026 |
| KLRS | PRESS-RELEASE | neutral | 4/10 | Kalaris Therapeutics reported Q1 2026 net loss per share of $(0.46), beating consensus of $(0.52) by 11.5%. The company | May 12, 2026 |
| ATAI | PRESS-RELEASE | mixed | 5/10 | AtaiBeckley reported Q1 2026 EPS of -$0.08, beating consensus of -$0.11 by 27%, and revenue of $954K, well above the $91 | May 12, 2026 |
| MGNX | 8-K | bullish | 7/10 | MacroGenics entered into a definitive agreement to sell its GMP manufacturing operations (CDMO business) to Bora Pharmac | May 12, 2026 |